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Objectives: With new classes of T2DM medications offering weight reduction in 
addition to better glycaemic control, HTA agencies expect fuller accounting of the 
impact of post-trial weight trajectory assumptions on cost-effectiveness. Four alter-
native scenarios were examined using the example of the novel SGLT-2 inhibitor 
canagliflozin (CANA) in the UK treatment setting. MethOds: The importance of 
alternative assumptions was illustrated using CANA 300mg versus glimepiride (GLIM; 
1mg titrated to 6mg or 8mg) in dual therapy with metformin simulated over 40 years 
using the ECHO-T2DM model loaded with patient characteristics, treatment effects, 
and adverse event rates from the DIA3009 trial, in which CANA 300mg reduced body 
weight by –5.7% versus GLIM over 52 weeks. HbA1c was assumed to drift annually by 
0.14% for CANA (similar to metformin in ADOPT), 0.24% for GLIM (as sulphonylurea 
in ADOPT), and 0.15% for rescue therapy with insulin (initiated when HbA1c > 7.5%). 
Upon treatment discontinuation, four alternative weight-trajectory assumptions were 
applied: (A) weight change maintained permanently; (B) CANA weight reduction dis-
appears fully at treatment discontinuation, GLIM weight-gain permanent; (C) GLIM 
weight-gain permanent, forced convergence of weight upon CANA discontinuation; 
(D) weight changes disappear fully at discontinuation for both treatments. A weight 
increase was applied when insulin was initiated and proportional weight changes 
were applied when insulin dose was titrated upwards. Results: CANA 300mg gener-
ated more QALYs at modest incremental cost, resulting in ICERs of £2,766 to £4,317 in 
the scenarios. Maintaining the benefits permanently (A) generated the largest QALY 
gain (0.243); complete elimination of benefits at discontinuation (D) offered the small-
est (0.198). The proportions of incremental QALYs attributable to weight differences 
were 34.4%, 19.5%, 18.9% and 17.4% for Scenarios A to D, respectively. cOnclusiOns: 
CANA 300mg was cost-effective in each of four weight scenarios following discon-
tinuation. Further work is required to define the most clinically plausible scenarios.
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Objectives: Dapagliflozin (Forxiga®) is the first sodium-glucose co-transporter-2 
inhibitor (SGLT-2) approved by the European Medicines Association, and positively 
assessed by the National Institute for Health and Care Excellence (NICE) for type 
2 diabetes mellitus (T2DM). This study evaluates the cost-effectiveness of dapagli-
flozin compared with a dipeptidyl-peptidase-IV (DPP-4) inhibitor when added to 
metformin in patients inadequately controlled on metformin alone. MethOds: 
The published and validated CARDIFF diabetes model was used to conduct the 
analysis. Clinical inputs were derived from a systematic review and network meta-
analysis. Based on clinical inputs and the United Kingdom Prospective Diabetes 
Study (UKPDS) equations, the model predicts disease progression and the number 
of micro- and macro-vascular complications, along with diabetes-specific and all-
cause mortality. The perspective of the National Health Service in England and Wales 
was adopted over a lifetime horizon. Local unit costs and utility data were assigned 
to the appropriate model parameters to calculate total Quality-Adjusted-Life-Years 
(QALYs) and costs. Univariate and probabilistic sensitivity analyses (PSA) were con-
ducted. Results: Compared to a DPP-4 inhibitor, dapagliflozin was associated with 
0.076 incremental QALYs (95%CI: –0.028; 0.146) at an additional cost of £412 (95%CI: 
-£212; £853); resulting in an incremental cost-effectiveness ratio (ICER) of £5,455 
per QALY gained. The univariate analyses showed that no input parameter change 
inflated the ICER above £15,000 per QALY. The PSA estimated that dapagliflozin 
has a 81% chance to increase QALYs and costs, a 9% chance to increase QALYs 
and save costs, a 4% chance to reduce QALYs and costs and a 6% chance to reduce 
QALYs and increase costs. At a willingness-to-pay threshold of £20,000 per QALY 
gained, dapagliflozin strategy had an 86% probability to be cost-effective in this 
setting. cOnclusiOns: Dapagliflozin in combination with metformin was shown 
to be a cost-effective treatment option for T2DM patients who are inadequately 
controlled with metformin mono-therapy.
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Objectives: The NICE reference case for T2DM requires cost-utility analysis with a 
lifetime horizon. The denominator in cost-utility outcomes is the incremental QALY, 
which is driven in most T2DM economic models by several key features, includ-
ing: life extension, micro- and macrovascular events, treatment and treatment-
related adverse events (AEs), and excess bodyweight. The aim of this analysis is to 
determine which factors most impact QALY gains in an analysis of CANA 300mg 
versus SITA 100mg when combined with metformin and sulphonylurea in the UK 
treatment setting. MethOds: The ECHO-T2DM model was used to simulate CANA 
versus SITA over 40 years. ECHO-T2DM was loaded with patient characteristics, 
treatment effects, and AE rates from the DIA3015 trial. HbA1c was assumed to drift 
upwards at an annual rate of 0.14% for CANA and SITA (similar to metformin in 
the ADOPT trial). CANA and SITA were discontinued and insulin initiated (annual 
drift 0.15% as in UKPDS) when patients failed to maintain HbA1c under 58 mmol/
mol (7.5%). Results: Hypothetical patients experienced 0.039 more QALYs when 
treated with CANA 300mg versus SITA 100mg. Because SITA had lower initial HbA1c 
lowering, it was associated with greater use of rescue medication. Patients treated 
initially with SITA, thus, had greater insulin-mediated HbA1c lowering over time so 
HbA1c values converged asymptotically (limiting differences in rates of microvas-
cular complications). There were relatively modest QALY benefits related to macro-
Carlo simulation techniques to describe the long-term incidence and progression 
of diabetes-related complications. It was used to simulate disease progression in 
a cohort of pediatric patients with baseline characteristics taken from published 
KAZAKHSTAN studies (mean age 10.4 years, duration of diabetes 4.1 years, mean 
HbA1c > 7.5%). Direct costs for 2013 were calculated from a third-party payer per-
spective. Discount rates of 5% per annum were applied to costs and 3% to clinical 
outcomes. Results: Mean undiscounted life expectancy of patients using CSII vs. 
MDI was increased by 3.58 years. The Incremental-Cost-Effectiveness-Ratio (ICER) 
for CSII was 3,935,375KZT per Quality-Adjusted-Life-Year gained based on direct 
costs only. CSII related therapy costs were partially offset by the savings due to the 
reduction in long-term complications, i.e.638,744KZT, mainly due to cardiovascu-
lar and renal diseases. Cumulative incidences of proliferative diabetic retinopathy, 
blindness, ESRD, and GRP were decreased by 25.3%, 5.6%, 28.3%, and 17.7%, respec-
tively. CSII treatment also delayed the average onset of ESRD (3.9 years), blindness 
(3.7 years), PVD (3.5 years), CHF (3.6 years), Neuropathy (3.4 years), first ulcer (4.0 
years), amputation (3.7 years), MI (3.5 years), and stroke (3.5 years). Extensive sensi-
tivity analyses showed the robustness of the results. cOnclusiOns: Using a payer’s 
perspective, our analysis showed that CSII is cost-effective over a lifetime horizon 
in children with Type 1 Diabetes in Kazakhstan (using a WTP threshold of 6,330,000 
KZT [3x GDP]) and can lead to an increase in life expectancy as well as delay and 
reduce long-term complications. When including indirect costs, CSII would be even 
more attractive from a societal perspective.
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Objectives: To assess the cost-effectiveness of using intralesional injection of 
recombinant human epidermal growth factor (rhEGF) for the treatment of severe 
non-healing diabetic foot ulcers (DFU) in highly-specialized inpatient department 
in Russian setting. MethOds: We developed a cost-effectiveness model based on 
hypothesis that use of intralesional injection of rhEGF in addition to standard treat-
ment of severe DFU (Wagner grade 3-4) would reduce the rate of amputations and 
related increased mortality in population of amputated DFU patients. For model 
inputs we used published data on the rates of amputation from retrospective study 
of intralesional injection of rhEGF and survival rates for patients with DFU with and 
without major amputations. Cost data was derived from the Russian retrospective 
study of real practice of inpatient treatment of severe DFU and reimbursement rates 
in Russian compulsory medical insurance system, cost of rhEGF treatment was pro-
vided by the manufacturer. Based on the model outputs we calculated incremental 
cost-effectiveness ratio (ICER) as the difference in costs to the difference in years 
lived during the 5-year period of observation by two cohorts of patients treated with 
only standard methods and with addition of rhEGF. Results: The use of rhEGF 
intralesional injection treatment may prevent 52 amputations and save 29.54 years 
of life in a cohort of 100 patients with severe DFU during subsequent 5-year period of 
observation. The ICER for rhEGF is estimated at EURO 27,200 per life year saved and 
does not exceed the acceptable threshold of three GDP per capita as recommended 
by WHO. The sensitivity analysis demonstrated that the results are most sensitive 
to the cost of rhEGF. cOnclusiOns: The model has demonstrated the acceptability 
of adoption of intralesional injection of rhEGF in addition to standard treatment for 
DFU in highly specialized inpatient departments.
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Objectives: To assess the cost-effectiveness of oral hypoglycaemic agents (micro-
nized glibenclamide, gliclazide, glimepiride and repaglinide) in the treatment of 
Russian patients with type 2 diabetes mellitus. MethOds: Based on the data from 
comparative studies (B. Wolffenbuttel et al., 1999; A. Holstein et al., 2001; O. Reshetko 
et al., 2007) the pharmacoeconomic profiles of glibenclamide and repaglinide, gliben-
clamide and glimepiride, glibenclamide and gliclazide were compared. It was revealed 
that glibenclamide and repaglinide, glibenclamide and gliclazide have equal efficacy 
and safety, so the cost-minimization analysis was performed. The cost-effective-
ness of glibenclamide and glimepiride was measured as total costs of medicines 
and expenses for ambulance calls for severe hypoglycemia per one patient without 
hypoglycaemic events. A one-year time horizon was adopted in the models. One-
way sensitivity analysis (SA) was carried out to assess the robustness of the results 
. Results: Compared to repaglinide and gliclazide, treatment with glibenclamide 
was associated with substantial budget savings (22,699.35 RUB and 3,566.05 RUB per 
one patient, respectively). Costs per one patient without hypoglycaemic events were 
1,137.17 RUB and 5,549.85 RUB in glibenclamide and glimepiride groups, respectively. 
Sensitivity analysis demonstrated that results are robust. cOnclusiOns: The pre-
sent study has demonstrated that administration of micronized glibenclamide is 
the most economically effective strategy in the treatment of Russian patients with 
type 2 diabetes mellitus. Treatment with micronized glibenclamide is associated 
with considerably lower costs as compared to repaglinide, glimepiride and gliclazide.
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